Merck’s has posted the full trial results for its first-in-class activin inhibitor for the treatment of pulmonary arterial hypertension, sotatercept. The final report supports last fall’s positive interim analysis, which I covered in the Clinical Pipeline.
The final analysis was just published in NEJM 👇

https://www.nejm.org/doi/full/10.1056/NEJMoa2213558

You can read my piece on it here

https://www.nature.com/articles/d41591-022-00109-w